Views: 1452 Downloads: 78

Yousef Alizadeh , Mitra Akbari , Soheil Soltanipour , Reza Soltani Moghadam , Abdolreza Medghalchi , Maryam Dourandeesh , Halleh Alizadeh

Abstract

This study investigated the possible therapeutic effects of oral rifampin on patients with acute Central Serous Chorioretinopathy (CSC). This clinical trial was a randomized placebo-controlled, double-masked research involving 30 patients with acute CSC. The patients were randomly assigned into two groups, one receiving 600 mg of oral rifampin once a day for a month and another being the matched placebo group. The Best Corrected Visual Acuity (BCVA), the subretinal fluid height at the posterior pole of the eye determined using spectral-domain optical coherence tomography (SD- OCT), and serum cortisol levels were assessed at baseline and an additional three months. The main outcome measures were the BCVA and subretinal fluid height and the secondary outcome measure was the serum cortisol level that was compared between groups.

At all follow-up times, significant improvements in BCVA and subretinal fluid resolution were found in both groups, but the differences between them were not statistically significant (P > 0.05). At baseline, the groups did not statistically differ in terms of mean 8 A.M. serum cortisol (C_8AM) (P = 0.81). Month 1, however, registered a significant difference in mean C_8AM between the groups (P = 0.03). At the end of the second month, this difference reverted to statistical nonsignificance (P = 0.06). The results suggested that the month-long treatment with oral rifampin exerted no beneficial effects on VA and subretinal fluid resolution in acute CSC patients. Such treatment, however, reduced the endogenous steroids of the oral rifampin group‎.

Citation Formats: